HRP20201683T1 - Imunogeni pripravak namijenjen upotrebi u terapiji - Google Patents
Imunogeni pripravak namijenjen upotrebi u terapiji Download PDFInfo
- Publication number
- HRP20201683T1 HRP20201683T1 HRP20201683TT HRP20201683T HRP20201683T1 HR P20201683 T1 HRP20201683 T1 HR P20201683T1 HR P20201683T T HRP20201683T T HR P20201683TT HR P20201683 T HRP20201683 T HR P20201683T HR P20201683 T1 HRP20201683 T1 HR P20201683T1
- Authority
- HR
- Croatia
- Prior art keywords
- aureus
- bacterium
- kda
- capsular saccharide
- immunogenic preparation
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 19
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 241000894006 Bacteria Species 0.000 claims 21
- 150000001720 carbohydrates Chemical class 0.000 claims 21
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 230000002265 prevention Effects 0.000 claims 11
- 208000015181 infectious disease Diseases 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 150000004676 glycans Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Imunogeni pripravak koji sadrži
i. kapsularni saharid tip 5 iz bakterije Staphilococcus aureus konjugiran s proteinskim nosačem kako bi tvorio konjugat kapsularnog saharida tip 5 iz bakterije S. aureus, gdje se konjugat kapsularnog saharida tip 5 iz bakterije S. aureus primjenjuje u dozi saharida od 3-50 µg, 5-25 µg, 3-20 µg, 3-12 µg, 5-10 µg, 7-20 µg, 7-15 µg ili 8-12 µg,
ii. kapsularni saharid tip 8 iz bakterije S. aureus konjugiran s proteinskim nosačem kako bi tvorio konjugat kapsularnog saharida tip 8 iz bakterije S. aureus, gdje se konjugat kapsularnog saharida tip 8 iz bakterije S. aureus primjenjuje u dozi saharida od 3-50 µg, 5-25 µg, 3-20 µg, 3-12 µg, 5-10 µg, 7-20 µg, 7-15 µg ili 8-12 µg,
iii. protein ClfA, ili njegov fragment, gdje je protein ClfA, ili njegov fragment, najmanje 90% istovjetan polipeptidnom slijedu u skladu s bilo kojim od SEQ ID NO: 3-12 ili 15-18 po njegovoj punoj duljini, te
iv. toksoid alfa,
naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom Staphilococcus aureus gdje se ljudskog pacijenta imunizira jednom dozom imunogenog pripravka.
2. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s patentnim zahtjevom 1, naznačen time što kapsularni saharid tip 5 iz bakterije S. aureus ima molekulsku težinu iznad 25 kDa, 40 kDa ili 50 kDa ili između 25-300 kDa, 50-250 kDa, 70-150 kDa, 25-125 kDa, 90-125 kDa, 30-100 kDa, 35-75KDa ili 40-70 kDa.
3. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što kapsularni saharid tip 8 iz bakterije S. aureus ima molekulsku težinu iznad 25 kDa, 40 kDa ili 50 kDa ili između 25-300 kDa, 50-250 kDa, 70-150 kDa, 25-125 kDa, 90-125 kDa, 30-100 kDa, 35-75KDa ili 40-70 kDa.
4. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je kapsularni saharid tip 5 iz bakterije S. aureus i/ili the kapsularni saharid tip 8 iz bakterije S. aureus O-acetiliran 50-100% ili 75-100%.
5. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što se omjer između polisaharida i proteina u konjugatu kapsularnog saharida tip 5 iz bakterije S. aureus kreće između 1:5 i 5:1 (tež./tež.) ili između 1:2 i 2:1 (tež./tež.), 1:2 do 1:5 (tež./tež.) ili 1:1 i 1:2 (tež./tež.).
6. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što se omjer između polisaharida i proteina u konjugatu kapsularnog saharida tip 8 iz bakterije S. aureus kreće između 1:5 i 5:1 (tež./tež.) ili između 1:2 i 2:1 (tež./tež.), 1:2 do 1:5 (tež./tež.) ili 1:1 i 1:2 (tež./tež.).
7. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je ista doza saharida za kapsularni saharid tip 5 iz bakterije S. aureus i kapsularni saharid tip 8 iz bakterije S. aureus prisutna u imunogenom pripravku.
8. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što protein ClfA, ili njegov fragment, sadrži aminokiselinsku zamjenu koja smanjuje sposobnost vezanja ClfA na fibrinogen.
9. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s patentnim zahtjevom 8, naznačen time što protein ClfA, ili njegov fragment, sadrži aminokiselinsku zamjenu na najmanje jednoj od aminokiselina Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Tyr474, Glu526 ili Val527.
10. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time što toksoid alfa ima aminokiselinski slijed najmanje 90% istovjetan sa SEQ ID NO: 1-2.
11. Imunogeni pripravak namijenjen upotrebi u liječenju ili sprječavanju infekcije bakterijom S. aureus u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što se jednu dozu imunogenog pripravka primjenjuje 5-60, 6-40, 7-30 ili 7-15 dana prije planiranog bolničkog postupka.
12. Imunogeni pripravak, naznačen time što sadrži kapsularni saharid tip 5 iz bakterije S. aureus konjugiran s proteinskim nosačem, kapsularni saharid tip 8 iz bakterije S. aureus konjugiran s proteinskim nosačem, protein ClfA, ili njegov fragment, gdje je protein ClfA, ili njegov fragment, najmanje 90% istovjetan polipeptidnom slijedu u skladu s bilo kojim od SEQ ID NO:3-12 ili 15-18 po njegovoj punoj duljini, te toksoid alfa, gdje je toksoid alfa prisutan u imunogenom pripravku u dozi od 5-50, 10-30, 5-15 ili 20-40 µg.
13. Postupak priprave imunogenog pripravka u skladu s patentnim zahtjevima 1-12, naznačen time što se sastoji u koracima a) konjugiranja kapsularnog saharida tip 5 iz bakterije S. aureus s proteinskim nosačem kako bi tvorio konjugat kapsularnog saharida tip 5 iz bakterije S. aureus, b) konjugiranja kapsularnog saharida tip 8 iz bakterije S. aureus konjugiran s proteinskim nosačem kako bi tvorio konjugat kapsularnog saharida tip 8 iz bakterije S. aureus, te c) kombiniranja konjugata kapsularnog saharida tip 5 iz bakterije S. aureus, konjugata kapsularnog saharida tip 8 iz bakterije S. aureus, proteina ClfA, ili njegovog fragmenta, gdje je protein ClfA, ili njegov fragment, najmanje 90% istovjetan polipeptidnom slijedu u skladu s bilo kojim od SEQ ID NO: 3-12 ili 15-18 po njegovoj punoj duljini, i toksoida alfa kako bi se dobilo imunogeni pripravak.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1310008.6A GB201310008D0 (en) | 2013-06-05 | 2013-06-05 | Immunogenic composition for use in therapy |
PCT/EP2014/061424 WO2014195280A1 (en) | 2013-06-05 | 2014-06-03 | Immunogenic composition for use in therapy |
EP14727541.6A EP3003363B1 (en) | 2013-06-05 | 2014-06-03 | Immunogenic composition for use in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201683T1 true HRP20201683T1 (hr) | 2020-12-25 |
Family
ID=48805771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201683TT HRP20201683T1 (hr) | 2013-06-05 | 2020-10-19 | Imunogeni pripravak namijenjen upotrebi u terapiji |
Country Status (24)
Country | Link |
---|---|
US (3) | US20160129101A1 (hr) |
EP (1) | EP3003363B1 (hr) |
JP (2) | JP2016524619A (hr) |
KR (1) | KR102266346B1 (hr) |
CN (1) | CN105517567A (hr) |
AU (1) | AU2014277027B2 (hr) |
BE (1) | BE1021938B1 (hr) |
BR (1) | BR112015029931B1 (hr) |
CA (1) | CA2912496C (hr) |
CY (1) | CY1123583T1 (hr) |
DK (1) | DK3003363T3 (hr) |
EA (1) | EA033488B1 (hr) |
ES (1) | ES2830785T3 (hr) |
GB (1) | GB201310008D0 (hr) |
HR (1) | HRP20201683T1 (hr) |
HU (1) | HUE051358T2 (hr) |
IL (1) | IL242584B (hr) |
LT (1) | LT3003363T (hr) |
MX (1) | MX2015016750A (hr) |
PL (1) | PL3003363T3 (hr) |
PT (1) | PT3003363T (hr) |
SG (1) | SG11201509406QA (hr) |
SI (1) | SI3003363T1 (hr) |
WO (1) | WO2014195280A1 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9931397B2 (en) * | 2005-06-27 | 2018-04-03 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
PL2493498T3 (pl) * | 2009-10-30 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8 |
MX2017007652A (es) * | 2014-12-10 | 2017-10-11 | Glaxosmithkline Biologicals Sa | Metodo de tratamiento. |
US11446371B2 (en) | 2015-11-05 | 2022-09-20 | The Texas A&M University System | Targeting of ligand binding sites in ClfA |
RU2689161C1 (ru) * | 2018-10-04 | 2019-05-24 | Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ получения бактериальных антигенов |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6294177B1 (en) | 1996-09-11 | 2001-09-25 | Nabi | Staphylococcus aureus antigen-containing whole cell vaccine |
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
CA2341177A1 (en) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
CA2344166C (en) | 1998-09-14 | 2008-11-18 | Nabi | Compositions of .beta.-glucans and specific igiv |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
WO2002026757A2 (en) | 2000-09-26 | 2002-04-04 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20030113350A1 (en) | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
NZ561879A (en) | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
AU2004257228B8 (en) | 2003-07-09 | 2009-01-08 | Life Technologies Corporation | Method for assaying protein-protein interaction |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
KR101270838B1 (ko) | 2004-05-11 | 2013-07-04 | 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 폭스겐트존하이트 벨지인 엔 스포츠 | 보조제로서의 나이세리아 메닌자이티디스 IgtB LOS |
EP2476433A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
AR060188A1 (es) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
GB0606416D0 (en) * | 2006-03-30 | 2006-05-10 | Glaxosmithkline Biolog Sa | Immunogenic composition |
WO2007145689A1 (en) * | 2006-06-12 | 2007-12-21 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
BRPI0906997A2 (pt) | 2008-01-31 | 2015-07-07 | Trinity College Dublin | Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica |
SI2445522T1 (sl) * | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
US9125951B2 (en) | 2009-06-22 | 2015-09-08 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
GB0913680D0 (en) * | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
JP2013506651A (ja) | 2009-09-30 | 2013-02-28 | ノバルティス アーゲー | Staphylococcus.aureus5型および8型莢膜多糖の結合体 |
PL2493498T3 (pl) | 2009-10-30 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8 |
ES2655701T3 (es) * | 2010-07-02 | 2018-02-21 | The University Of Chicago | Composiciones y métodos relacionados con variantes de la proteína A (SpA) |
CA2819120C (en) * | 2010-12-22 | 2016-07-05 | Wyeth Llc | Stable immunogenic compositions of staphylococcus aureus antigens |
-
2013
- 2013-06-05 GB GBGB1310008.6A patent/GB201310008D0/en not_active Ceased
-
2014
- 2014-06-03 JP JP2016517263A patent/JP2016524619A/ja active Pending
- 2014-06-03 EA EA201592040A patent/EA033488B1/ru not_active IP Right Cessation
- 2014-06-03 US US14/893,685 patent/US20160129101A1/en not_active Abandoned
- 2014-06-03 WO PCT/EP2014/061424 patent/WO2014195280A1/en active Application Filing
- 2014-06-03 AU AU2014277027A patent/AU2014277027B2/en active Active
- 2014-06-03 SI SI201431695T patent/SI3003363T1/sl unknown
- 2014-06-03 ES ES14727541T patent/ES2830785T3/es active Active
- 2014-06-03 PL PL14727541T patent/PL3003363T3/pl unknown
- 2014-06-03 LT LTEP14727541.6T patent/LT3003363T/lt unknown
- 2014-06-03 MX MX2015016750A patent/MX2015016750A/es unknown
- 2014-06-03 BE BE2014/0416A patent/BE1021938B1/fr not_active IP Right Cessation
- 2014-06-03 PT PT147275416T patent/PT3003363T/pt unknown
- 2014-06-03 CA CA2912496A patent/CA2912496C/en active Active
- 2014-06-03 CN CN201480044279.1A patent/CN105517567A/zh active Pending
- 2014-06-03 SG SG11201509406QA patent/SG11201509406QA/en unknown
- 2014-06-03 HU HUE14727541A patent/HUE051358T2/hu unknown
- 2014-06-03 DK DK14727541.6T patent/DK3003363T3/da active
- 2014-06-03 EP EP14727541.6A patent/EP3003363B1/en active Active
- 2014-06-03 KR KR1020157037240A patent/KR102266346B1/ko active IP Right Grant
- 2014-06-03 BR BR112015029931-8A patent/BR112015029931B1/pt active IP Right Grant
-
2015
- 2015-11-12 IL IL242584A patent/IL242584B/en active IP Right Grant
-
2016
- 2016-11-15 US US15/351,847 patent/US20170056490A1/en not_active Abandoned
-
2017
- 2017-12-05 US US15/832,240 patent/US20180104322A1/en not_active Abandoned
-
2019
- 2019-03-06 JP JP2019040307A patent/JP6773830B2/ja active Active
-
2020
- 2020-10-19 HR HRP20201683TT patent/HRP20201683T1/hr unknown
- 2020-11-11 CY CY20201101066T patent/CY1123583T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2912496A1 (en) | 2014-12-11 |
EP3003363A1 (en) | 2016-04-13 |
EA201592040A1 (ru) | 2016-06-30 |
US20160129101A1 (en) | 2016-05-12 |
CN105517567A (zh) | 2016-04-20 |
EP3003363B1 (en) | 2020-08-19 |
AU2014277027B2 (en) | 2017-07-20 |
IL242584B (en) | 2021-06-30 |
GB201310008D0 (en) | 2013-07-17 |
HUE051358T2 (hu) | 2021-03-01 |
KR102266346B1 (ko) | 2021-06-17 |
US20170056490A1 (en) | 2017-03-02 |
BE1021938B1 (fr) | 2016-01-27 |
US20180104322A1 (en) | 2018-04-19 |
MX2015016750A (es) | 2016-04-13 |
CY1123583T1 (el) | 2022-03-24 |
DK3003363T3 (da) | 2020-11-09 |
EA033488B1 (ru) | 2019-10-31 |
JP6773830B2 (ja) | 2020-10-21 |
PL3003363T3 (pl) | 2021-04-06 |
PT3003363T (pt) | 2020-11-16 |
JP2016524619A (ja) | 2016-08-18 |
ES2830785T3 (es) | 2021-06-04 |
BR112015029931B1 (pt) | 2021-01-12 |
CA2912496C (en) | 2023-01-17 |
SG11201509406QA (en) | 2015-12-30 |
JP2019123720A (ja) | 2019-07-25 |
KR20160018604A (ko) | 2016-02-17 |
SI3003363T1 (sl) | 2020-12-31 |
AU2014277027A1 (en) | 2015-12-24 |
WO2014195280A1 (en) | 2014-12-11 |
LT3003363T (lt) | 2020-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201683T1 (hr) | Imunogeni pripravak namijenjen upotrebi u terapiji | |
BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
EA200701519A1 (ru) | Живая аттенуированная ротавирусная вакцина для перорального введения | |
HRP20230504T1 (hr) | Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma | |
JP2015231997A5 (hr) | ||
BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
JP2016528247A5 (hr) | ||
IL294463A (en) | Methods for treating or preventing eye conditions | |
WO2017100700A3 (en) | Peptides for renal therapy | |
JP2019203035A5 (hr) | ||
HRP20130065T1 (hr) | Cjepivo protiv salmonele za perad | |
BR112018014027A2 (pt) | composições e métodos para administração intravenosa de 2-bromo-1-(3,3-dinitroazeditin-1-il)etanona | |
HRP20230182T1 (hr) | Modulatori aktivnosti komplementa | |
MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
BR112013032911A2 (pt) | leucotoxina e/d como um novo agente anti-inflamatório e microbicida | |
RU2015106742A (ru) | Композиции, содержащие химерные молекулы ospa и способы их применения | |
RU2013157933A (ru) | Композиции, включающие антибактериальное средство и тазобактам | |
BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
BRPI0410374A (pt) | composição farmacêutica que compreende valsartano |